Radionuclide Therapy
A cancer treatment targeting proteins that control how cancer cells grow, divide, and spread, by using therapeutic radionuclides. The foundation of precision medicine.
In Radionuclide Therapy, a specific radionuclide is linked to a cell-targeting molecule, to design a systemic treatment, reaching cells throughout the body by travelling through the bloodstream.
The biological action of a radiopharmaceutical is determined by the form of ionizing radiation emitted by the radionuclide. While imaging procedures in nuclear medicine require radionuclides that will emit γ (gamma) radiation able to penetrate the body, a different class of radionuclides possessing optimal relative biological effectiveness is needed for radionuclide therapy. The radionuclides best suited for tumour therapy are those emitting ionizing radiation with short penetration into the tissue, such as α (alpha) or β (beta) emitters, which release their energy in the proximity of their targets.
Our Radiochemistry Laboratories are licensed facilities, to import and handle a wide range of radioisotopes (both short-lived and long-lived) and has long established collaboration with the top isotope providers worldwide.
Services include:
- Radiolabelling assays for a wide range of compounds (incl. QCs), such as peptides, nanoparticles, proteins, antibodies etc.
- Radiolabelling assays for a wide range of isotopes – α (alpha), β (beta) & γ (gamma) emitters
- Kinetic stability assays
- New protocol set up
- Conjugation assays
- Access to a wide range of clinical radio-pharmaceutical kits
